Welcome to our dedicated page for Sanuwave Health SEC filings (Ticker: SNWV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sanuwave Health, Inc. (SNWV) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K, proxy statements, and other regulatory documents. Sanuwave is a Nevada corporation whose common stock trades on NASDAQ under the symbol SNWV, and its filings offer detailed information on operations, governance, and financing.
Recent Forms 8-K describe results of operations and financial condition for specific quarters, including press releases announcing revenue, gross margin, operating income, and non-GAAP metrics such as EBITDA and Adjusted EBITDA. Other 8-K filings cover material definitive agreements, such as a secured credit facility with JPMorgan Chase Bank, N.A. that includes a term loan and revolving credit facility, and the termination of a prior debt facility with NH Expansion Credit Fund Holdings LP.
Additional 8-K items document corporate actions and governance events, including changes in executive officers, separation and release agreements, stockholder meeting results, and amendments to the 2024 Equity Incentive Plan. One filing also describes a license and option agreement related to intravascular shockwave patents and the subsequent exercise of the option by the licensee, resulting in a cash payment to Sanuwave.
Investors interested in capital structure and shareholder matters can review the company’s definitive proxy statement (DEF 14A), which discusses director elections, ratification of the independent registered public accounting firm, advisory votes on executive compensation, and details of the reverse stock split of Sanuwave’s common stock.
On Stock Titan, these filings are updated from the SEC’s EDGAR system, and AI-powered tools can help summarize key points, highlight significant items in Forms 8-K, and clarify the implications of proxy proposals and financing agreements. This allows readers to quickly understand how Sanuwave’s regulatory disclosures relate to its advanced wound care and regenerative medicine business.
Opaleye-related entities reported open-market sales of SANUWAVE Health, Inc. common stock. On April 17, Opaleye, L.P. sold 11,267 shares at a weighted average price of $20.4611 per share, and a separately managed account sold 5,000 shares at the same price.
On April 21, Opaleye, L.P. sold an additional 202 shares at a weighted average price of $20.5025. Following these transactions, Opaleye, L.P. held 954,798 shares, and the managed account held 10,000 shares. Opaleye Management Inc. disclaims beneficial ownership beyond its pecuniary interest.
Sanuwave Health, Inc. reported preliminary revenue for the quarter ended March 31, 2026 of $9.6–$9.7 million, an increase of 3–4% over the same quarter in 2025 and in line with its prior Q1 guidance.
Management noted that several larger deals slipped out of the quarter but remain active, contributing to results landing toward the lower end of the guided range. The company highlighted disruption in advanced wound care from reimbursement changes for skin substitutes and allografts, which has caused some customers to pause or scale back activity.
Sanuwave described strong practitioner interest in its Ultramist technology at a recent wound care conference and indicated it plans to “lean in” to the market rather than pull back. The company emphasized that these figures are preliminary and may change when full Q1 results are reported in May.
SANUWAVE Health, Inc. director Tyler James reported receiving a grant of stock options. The award covers 3,208 options, each giving the right to buy one share of common stock at an exercise price of $17.29 per share. According to the filing, these options were fully vested on the grant date and expire on March 31, 2031. Following this grant, James holds 3,208 stock options directly, with no common stock purchases or sales reported in this filing.
SANUWAVE Health, Inc. reported that Chief Executive Officer Frank C. Morgan received a grant of stock options. He was awarded options to purchase 3,208 shares of common stock at an exercise price of $17.29 per share, fully vested on the grant date. These options expire on March 31, 2031, and following this grant he holds 3,208 stock options directly.
SANUWAVE Health, Inc. director Jeffrey Blizard reported a grant of stock options as part of his compensation. On March 31, 2026, he acquired 3,208 stock options, each giving the right to buy one share of common stock at an exercise price of $17.29.
The options were fully vested at the grant date and expire on March 31, 2031. Following this grant, Blizard holds 3,208 derivative securities directly, reflecting a routine award rather than an open-market purchase or sale.
SANUWAVE Health director Gregory Matthew Bazar received a grant of stock options covering 3,208 shares of Common Stock. The options have an exercise price of $17.29 per share and were fully vested on the grant date.
The options expire on March 31, 2031, and give him the right to buy up to 3,208 shares if exercised.
SANUWAVE Health, Inc. director Ian D. Miller received a grant of stock options covering 3,609 shares of common stock. The options have an exercise price of $17.29 per share, were fully vested on the grant date, and expire on March 31, 2031. Following this compensation award, Miller holds 3,609 derivative securities directly, with no related share sales or open-market purchases reported in this filing.
SANUWAVE Health Inc Schedule 13G/A: The Vanguard Group filed Amendment No. 1 reporting 0 shares and 0% beneficial ownership of SANUWAVE common stock following an internal realignment. The filing states this change is "in accordance with SEC Release No. 34-39538 (January 12, 1998)." The amendment is signed by Ashley Grim on 03/27/2026.
Sanuwave Health reported record results for Q4 and full year 2025, with revenue of $13.4 million in Q4, up 29.7%, and full-year revenue of $44.1 million, up 35.0% from 2024. UltraMIST systems and consumables drove nearly all sales.
Q4 2025 gross margin was 74.7%, affected by a $0.5 million PACE inventory write-off, while full-year gross margin improved to 77.1% from 75.2%. Q4 operating income was $2.0 million, and full-year operating income rose to $4.9 million.
Net income reached $7.7 million in Q4 and $11.8 million for 2025, compared with net losses in 2024. Adjusted EBITDA was $4.8 million for Q4 and $13.6 million for 2025. The company guides 2026 revenue to $51.0–55.0 million, implying 16–25% growth.
Sanuwave Health reports strong growth and significant accounting changes in its annual report for the year ended December 31, 2025. Revenue reached $44.1 million, up 35% from $32.6 million in 2024, driven almost entirely by its UltraMIST ultrasound wound care system and consumables, which contributed about 99% of revenue.
The company restated prior-year and interim financial statements after identifying errors in sales tax accounting and revenue recognition for extended warranties. Management concluded these errors were material and that earlier reports should no longer be relied upon. Sanuwave also disclosed material weaknesses in internal control over financial reporting and ineffective disclosure controls.
Despite a history of losses, Sanuwave executed a secured debt refinancing in 2025 and generated net income of $11.8 million with positive operating income for both 2024 and 2025. Management believes cash flows and existing cash will fund operations and debt service for at least twelve months, while acknowledging that failure to sustain performance or financing access could again pressure its liquidity.